Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AYTU with free AI briefings, catalyst countdowns, and dilution alerts.

AYTU · AYTU BIOPHARMA, INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$26.3M Cash on Hand
CF+ Cash Runway
Follow AYTU by email Get an email when AYTU reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AYTU, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ADZENYS XR-ODT Attention Deficit Hyperactivity Disorder Phase 4 · NCT07169162 Withdrawn
Enzastaurin Vascular Ehlers-Danlos Syndrome Phase 3 · NCT05463679 Suspended

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AYTU holds $26.3M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AYTU files for a raise →

👥 Who Owns AYTU

Insiders 5.1% Institutions (46 holders) 36.3% Public and other holders 58.6%
HolderTypeShares% of sharesAs of
Nantahala Capital Management, LLC Institution (13G, 5%+) 1,086,812 10.00% 2025-06-06
AWM Investment Company, Inc. Institution (13G, 5%+) 619,574 5.70% 2025-12-31
Joshua R. Disbrow
Chief Executive Officer, Director · +38,000 options
Insider 237,203 2.18% 2026-07-28
Jarrett Disbrow
Chief Business Officer · +7,000 options
Insider 76,568 0.70% 2026-07-28
Ryan J Selhorn
Chief Financial Officer
Insider 74,743 0.69% 2026-07-28
Greg Pyszczymuka
Chief Commercial Officer · +7,000 options
Insider 56,102 0.52% 2026-07-28
Carl Dockery
Director
Insider 31,152 0.29% 2026-07-28
Vivian H Liu
Director
Insider 29,825 0.27% 2026-07-28
Abhinav Jain
Director
Insider 29,500 0.27% 2026-07-28
John Jr. Donofrio
Director
Insider 23,762 0.22% 2026-07-28

Share count 10,868,208 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AYTU picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AYTU and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.